Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Last trade$201.45
Day change+$3.45 (+1.74%)
Day range$196.55 – $201.59
Volume999,966
Market cap$29.94B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$29.94B
Price / earnings
33.45×
Price / book
9.52×
Price / sales
6.6×
EV / sales
6.71×
EV / EBITDA
24.41×
Profitability
Earnings per share
$5.92
Return on assets
13.14%
Return on equity
28.46%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.57×
Current ratio
2.63×
Quick ratio
2.05×
Cash ratio
1.12×
Cash flow
Price / cash flow
24.34×
Price / free cash flow
28.32×
Free cash flow
$1.06B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ILMN, quarterly periods
Line item
Q3 FY2026 Sep 27, 2026
Q2 FY2026 Jun 28, 2026
Q1 FY2026 Mar 29, 2026
Q4 FY2025 Dec 28, 2025
Q3 FY2025 Sep 28, 2025
Q2 FY2025 Jun 29, 2025
Q1 FY2025 Mar 30, 2025
Q4 FY2024 Dec 29, 2024
Revenue
$1.13B
$1.16B
$1.09B
$1.16B
$1.08B
$1.06B
$1.04B
$1.1B
Cost of revenue
$299M
$389M
$370M
$400M
$351M
$364M
$358M
$376M
Gross profit
$830M
$770M
$721M
$759M
$733M
$695M
$683M
$728M
Selling, general and administrative
$281M
$273M
$272M
$309M
$277M
$234M
$267M
$279M
Research and development
$244M
$252M
$240M
$239M
$229M
$247M
$252M
$256M
Total operating expenses
$525M
$525M
$512M
$558M
$506M
$481M
$519M
$553M
Operating income
$305M
$245M
$209M
$201M
$227M
$214M
$164M
$175M
Interest expense
-$24M
-$24M
-$24M
-$26M
-$25M
-$25M
-$25M
-$25M
Income before taxes
$264M
$260M
$157M
$377M
$220M
$306M
$182M
$187M
Income taxes
$44M
$53M
$23M
$43M
$70M
$71M
$51M
$0
Net income
$220M
$207M
$134M
$334M
$150M
$235M
$131M
$187M
Net income attributable to common shareholders
$220M
$207M
$134M
$334M
$150M
$235M
$131M
$187M
EBITDA
$414M
$278M
$278M
$277M
$328M
$248M
$233M
$264M
Basic earnings per share
$1.46
$1.37
$0.88
$2.21
$0.98
$1.49
$0.83
$1.18
Diluted earnings per share
$1.43
$1.35
$0.87
$2.17
$0.98
$1.49
$0.82
$1.18
Recent news
Company coverage with links to the original publishers.
A comparison of Regeneron (REGN) and Illumina (ILMN) in the biomedical and genetics sector reveals that Regeneron presents a better value opportunity. REGN has a Zacks Rank of #2 (Buy) with improving earnings outlook, a forward P/E of 15.74, and a Value grade of B. ILMN has a Zacks Rank of #3 (Hold) with a forward P/E of 44.00 and a Value grade of D, making it significantly more expensive on multiple valuation metrics.
The First Trust NYSE Arca Biotechnology ETF (FBT) is reviewed as a passively managed fund offering broad exposure to the biotech sector with $3.1 billion in assets. The ETF has delivered strong year-to-date performance of 33.68% and one-year returns of 43.62%, though it carries higher risk with a beta of 0.68 and standard deviation of 20.77%. FBT received a Zacks ETF Rank of 2 (Buy) and is compared to competitors XBI and IBB, which have larger asset bases and lower expense ratios.
Three major healthcare companies—Illumina, Tempus AI, and Novartis—raised their FY26 guidance following positive Q3 earnings results. Illumina reported 4.2% YoY revenue growth driven by strong clinical demand and NovaSeq X placements. Tempus AI delivered record revenue with 23% YoY growth, particularly strong in its Data & Applications segment. Novartis improved its profitability outlook despite generic competition pressures.
Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify high-performing stocks. The Style Scores rate stocks on value, growth, and momentum characteristics, with the VGM Score combining all three methodologies. Illumina (ILMN) is highlighted as a stock to watch with a #3 Hold rank and B VGM Score, featuring strong growth prospects with forecasted 11.6% year-over-year earnings growth.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.